1. Home
  2. ADAG vs PMM Comparison

ADAG vs PMM Comparison

Compare ADAG & PMM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$3.65

Market Cap

254.4M

Sector

Health Care

ML Signal

HOLD

Logo Putnam Managed Municipal Income Trust

PMM

Putnam Managed Municipal Income Trust

HOLD

Current Price

$6.30

Market Cap

258.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADAG
PMM
Founded
2011
1989
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
254.4M
258.7M
IPO Year
2020
N/A

Fundamental Metrics

Financial Performance
Metric
ADAG
PMM
Price
$3.65
$6.30
Analyst Decision
Strong Buy
Analyst Count
4
0
Target Price
$8.25
N/A
AVG Volume (30 Days)
234.0K
113.0K
Earning Date
04-01-2026
01-01-0001
Dividend Yield
N/A
4.68%
EPS Growth
N/A
N/A
EPS
N/A
0.23
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$27.26
Revenue Growth
N/A
N/A
52 Week Low
$1.44
$5.77
52 Week High
$4.75
$6.52

Technical Indicators

Market Signals
Indicator
ADAG
PMM
Relative Strength Index (RSI) 48.42 59.50
Support Level $3.40 $6.06
Resistance Level $3.99 $6.35
Average True Range (ATR) 0.26 0.07
MACD -0.02 0.01
Stochastic Oscillator 56.09 82.14

Price Performance

Historical Comparison
ADAG
PMM

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

Share on Social Networks: